Navigation Links
Angiotech announces exclusive distribution agreement with B. Braun for Angiotech's proprietary Quill(TM) SRS product line
Date:5/3/2010

personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by patents owned or controlled by third parties; our ability to obtain rights to technology from licensors; liability for patent claims and other claims asserted against us; our ability to obtain and enforce timely patent and other intellectual property protection for our technology and products; the ability to enter into, and to maintain, corporate alliances relating to the development and commercialization of our technology and products; market acceptance of our technology and products; our ability to successfully manufacture, market and sell our products; the availability of capital to finance our activities; our ability to restructure and to service our debt obligations; and any other factors referenced in our other filings with the applicable Canadian securities regulatory authorities or the Securities and Exchange Commission ("SEC"). For a more thorough discussion of the risks associated with our business, see the "Risk Factors" section in our annual report for the year ended December 31, 2009 filed with the SEC on Form 10-K.

Given these uncertainties, assumptions and risk factors, investors are cautioned not to place undue reliance on such forward-looking statements. Except as required by law, we disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained in this press release to reflect future results, events or developments.

(C)2010 Angiotech Pharmaceuticals, Inc. All Rights Reserved.

About the Quill(TM) Self-Ret
'/>"/>

SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... NC (PRWEB) January 15, 2014 DTS ... to its Online Web Portal for Life Science organizations who ... to specify the subject matter of their documents in advance ... will help reduce time-to-delivery of translations, often a critical factor ...
(Date:1/14/2014)... Doylestown, PA (PRWEB) January 14, 2014 Date: ... p.m. , Location: Warrington Country Club, 1360 Almshouse Road, Warrington, ... only national nonprofit organization solely dedicated to finding a cure ... those affected worldwide, will host its annual Crystal Ball on ...
(Date:1/14/2014)... EquitiesIQ, a leading informational research provider, ... is an emerging biomedical company acquiring, developing, manufacturing, and ... , Free report download: http://equitiesiq.com/reports/alliqua/ , In ... team and Board, which launched the company’s new strategy ...
(Date:1/14/2014)... , Jan. 14, 2014  RXi Pharmaceuticals Corporation ... developing and commercializing innovative therapies addressing major unmet ... it received the Notice of Allowance from the ... unique self-delivering RNAi compounds (sd-rxRNA®), for the treatment ...
Breaking Biology Technology:DTS Improves Efficiency for Life Science Document Translations 2Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3
... DETROIT, Oct. 23 Caraco Pharmaceutical,Laboratories, Ltd. (Amex: ... and,first six months of Fiscal 2009 of $122.2 million ... $76.8 million, respectively,for the corresponding periods of Fiscal 2008. ... periods of Fiscal 2008. Pre-tax income,grew to $12.3 million ...
... MIAMI, Oct. 23 NOVIS Pharmaceuticals, Inc. today,announced ... been,appointed Chairman of the Board. The appointment was ... meeting and is effective immediately., (Logo: ... to take on this role at NOVIS, and ...
... Ltd (BioWisdom),the market leader in delivering healthcare ... release of OmniViz,Visualization Software for Patent Specialists., ... in competitive business and,technical intelligence analyses to ... can turn the analysis of thousands of,patents ...
Cached Biology Technology:Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 2Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 3Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 4Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 5Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 6Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 7Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal 2009 8NOVIS Announces Appointment of John J. Arlotta as Chairman 2
(Date:4/17/2014)... study suggests that fish consumption advisories for expecting ... long-lived contaminants like persistent organic pollutants (POPs). ... researchers including University of Toronto Scarborough PhD student ... how different levels of environmental contamination, a mother,s ... in the body influenced exposure in her children. ...
(Date:4/17/2014)... release is available in German . ... to recognise objects; they also provide us with a continuous ... turn around, fall or sit still in a car ... trace on our retinas. Seemingly without effort, our brain calculates ... a stable position and a steady gaze during our own ...
(Date:4/17/2014)... The White House honored Clemson professor Rajendra Singh ... efforts to promote and expand solar deployment in ... the D. Houser Banks Professor of Electrical and ... Silicon Nanoelectronics, is considered a local hero leading ... and economic opportunity in solar power and driving ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4White House honors Clemson professor as 'Champion of Change' for solar deployment 2
... PARK, Maryland A University of Maryland-led team of ... the impacts of climate change could affect civil conflicts. ... between conflict, socio-economic conditions and climate. They will use ... The U.S. Department of Defense is funding the ...
... rid of excess energy through the production of hydrogen. Biologists at ... absence of oxygen. For this, they need the messenger molecule nitric ... blood cells of humans. With colleagues at the UC Los Angeles, ... Haemoglobin an old protein in a new look ...
... into the human genome more readily in tumors than ... from the University of Maryland School of Medicine,s Institute ... from the Human Genome Project, the 1,000 Genomes Project ... phenomenon of lateral gene transfer (LGT), the transmission of ...
Cached Biology News:DoD-funded research: Can climate change heat up conflict? 2When green algae run out of air 2Bacterial DNA may integrate into human genome more readily in tumor tissue 2
DNase I (Deoxyribonuclease I) digests single- and double-stranded DNA to oligodeoxyribonucleotides. Ribonuclease activity has been reduced to non-detectable levels....
... strain containing an overproducing clone of M-MLV ... catalyzes the polymerization of DNA using template ... of large mRNAs, >10 kb, may be ... lower RNase H activity than AMV Reverse ...
... DNase is a preparation of deoxyribonuclease ... DNA to produce 3-hydroxyl oligonucleotides. This ... applications where maintaining the integrity of ... qualified for use with the Core ...
...
Biology Products: